ArticlePloS one2025
The efficacy of Netrod Six-electrode Radiofrequency Renal Denervation system: mathematical modeling, phantom experiments and animal studies.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The principle of NetrodTM Renal Denervation RF Generator is based on the heating of radiofrequency electrodes to achieve the therapeutic temperature for peripheral nerve ablation with minimal impact on intra-arterial blood flow. The extravascular heat distribution and continuous ablation were evaluated using COMSOL Multiphysics with an idealized 3D model and validated in an ex vivo experiment. The safety of ablation was verified by H&E staining of a hypertensive dog model in the treatment group of animal experiments, and changes in blood pressure before and after the procedure(assessed at 7, 30, and 60 days in animal experiments) were used to characterize the efficacy. The simulation results showed that the maximum injury depth range of the NetrodTM Six-electrode is 5.08mm and the depth of the ablation zone obtained in the Phantom experiment was 3-6mm. Circumferential coverage was up to 91.99% and the ablation zone was continuous. In animal experiments, eight animals in the treatment group had significantly lower blood pressure (88.9%). Nerve cells in nerve bundles showed vacuolar changes and thickening of peripheral sheaths after peripheral nerve ablation of renal arteries.The NetrodTM Six-electrode presented here has potential to effectively and safely ablate renal nerves. The demonstrated efficacy and safety in animal models provide a foundation for clinical trials in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.